This study is testing futibatinib (TAS-120), an oral targeted therapy, in people with advanced cholangiocarcinoma (bile duct cancer) that has specific genetic changes called FGFR2 fusions or rearrangements. You may be eligible if you have already received at least one gemcitabine and platinum-based chemotherapy. The study aims to confirm the benefits and evaluate the safety and effectiveness of two different doses of futibatinib (16 mg and 20 mg). Success will be measured by how many participants respond to the treatment, assessed 12 months after the study ends. This study is currently recruiting 120 participants.

Study design

This is an open-label, multinational, randomized Phase 2 study. Participants will be assigned by chance to receive either 16 mg or 20 mg of futibatinib daily.

What's involved

You will take futibatinib daily in 21-day cycles. Treatment continues until your disease progresses or other withdrawal criteria are met.

Compensation

Not stated in the trial record.

Follow-up

Your response to treatment will be assessed 12 months after the study completion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.